Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Of 223 patients with intracranial metastases, 161 underwent removal of a presumed solitary lesion and 29 were treated by burr-hole biopsy. Results of radical surgery were better than those of biopsy alone in terms of survival. Quality and duration of survival were poorer in patients who had infratentorial metastases removed than in those who underwent surgery for supratentorial metastases. In this second group only patients with breast cancer benefited from surgery, though a few women with bronchial carcinoma also did well. The interval removal of a primary tumour and development of intracranial symptoms did not influence outcome. Evidence of a previous primary tumour should not lead to the assumption that intracranial symptoms are caused by a metastasis.
 ...
PMID:Management of intracranial metastases. 65 88

This freeze-fracture study was performed in 3 astrocytomas, 6 glioblastomas, 2 ependymomas, 3 medulloblastomas, 1 cerebellar sarcoma, 3 germinomas, and 1 medulloepithelioma. The number of nuclear pores/mum2 nuclear membrane was not correlated with biological malignancy. Fracture faces A and B were discernible in nuclear, Golgi and rough endoplasmic reticulum (ER), mitochondrial surface, and plasma membranes. Fenestrae were evident in Golgi and ER membranes. The transitional zone of cristae from the inner surface membrane appeared as a circular hole and broken-off neck on faces A and B of the inner surface membrane, respectively. The decrease in number of membrane particles in the plasma membrane seemed to correlate with the frequency of metastases, and, in addition, the membrane particles appeared to cluster in glioblastoma, medulloblastoma, and medulloepithelioma. The gap junctions were abundant in astrocytomas, moderate in number in ependymomas and germinomas, and rare in glioblastomas, cerebellar sarcoma, and medulloepithelioma. Tight junctions were often found in germinomas and medulloepithelioma, and rarely in ependymomas.
 ...
PMID:Freeze-fracture study of human brain tumors. 117 38

There is a well documented relationship between small cell carcinoma of the lung and the amine precursor uptake and decarboxylation system of endocrine cells (APUD). We attempted to exploit this association by employing the unique radiopharmaceutical, 131I-MIBG, which is recognized and taken up by the APUD system to monitor disease activity in patients with small cell carcinoma of the lung. A total of eight patients with biopsy proven, metastatic small cell carcinoma of the lung were studied. 131I-MIBG was synthesized in our laboratory by reacting metaiodobenzylamine hydrochloride with cyanamide with subsequent solid phase radioiodination. A dose of 0.5 mCi radiopharmaceutical was injected and images obtained on a large field of view gamma camera with a high energy parallel hole collimator at 2, 24, and either 48 or 72 h. Images were compared with known focal areas of metastatic disease demonstrable on computed tomographic scan, chest roentgenogram or bone scan. We were unable to detect reproducible correlations between the images produced by conventional radiographic techniques and the images produced by our radiopharmaceutical. We conclude that this agent will probably not be useful for localization of metastatic small cell lung carcinoma.
 ...
PMID:Iodine-131 MIBG scintigraphy in small cell lung cancer. 256 70

A tumor model is presented to study the biokinetics and localization of radiolabeled monoclonal antibodies (MAb) in the nude rat (Rowett RNu/RNu) heterotransplanted with human melanoma metastases. The nude rat is larger, less sensitive, and lives longer than the nude mouse. It is, therefore, well suited for in vivo studies of tumor localization with radiolabeled monoclonal antibodies. The tumor-to-host weight ratio was closer to the human situation for the nude rat than for the mouse, and quantitative imaging could be performed with a parallel hole collimator. We followed the antibody biokinetics for as long as 8 days, with repeated blood sampling and imaging. Specific uptake of MAb was higher in tumor tissue than in all other tissues except blood. Initial high uptake was also recorded in the bone marrow. The lymph glands showed a slow uptake of specific and control antibody. A simple in vitro correction procedure is described to calculate the corrected specific tissue uptake (STUcorr) that takes the blood activity into account. Thus it was shown that 80% of the tissue uptake in the dissected liver at 30 hr was due to labeled antibodies circulating in the blood. The specific tissue uptake ratio of antibodies 96.5 and OKT3 (nonspecific control) was unity for all other organs except for tumor tissue, where the ratio was greater than two and even higher when correction for blood content of labeled antibody was made.
 ...
PMID:Biokinetics of radiolabeled monoclonal antibodies in heterotransplanted nude rats: evaluation of corrected specific tissue uptake. 273 3

Currently, three criteria are accepted as indications for prophylactic internal fixation of metastatic disease in long bone, including lesions (a) destroying 50% or more of the cortex; (b) 2.5 cm or greater in diameter; or (c) with pain unrelieved by radiation therapy. Using an oblong defect configuration in which one half of the cross-sectional area was destroyed, canine femora were torsion-tested at high speed to determine (a) the actual strength reduction incurred by a lesion destroying 50% of the cortical circumference, and (b) the effects and benefits of internal fixation using polymethylmethacrylate and/or a six-hole compression plate on such a defect. The femurs with a 50% circumferential cortical defect demonstrated only 12.7 +/- 3.8% of intact strength. Defects treated with a combination of plating (all screws bicortical) and polymethylmethacrylate (torque to failure 4.39 +/- 0.90 times greater than the defect alone or TE/TD = 4.39 +/- 0.90) were statistically stronger than defects treated with polymethylmethacrylate alone (TE/TD = 2.48 +/- 0.66; p less than 0.025) or by plating alone (TE/TD = 2.61 +/- 0.91; p less than 0.025), but torque-to-failure was only increased to approximately 56% of an intact bone. Plated intact bones (TE/TD = 5.33 +/- 0.41) were significantly weaker than intact bones (TE/TD = 8.50 +/- 2.52; p less than 0.001). Our results substantiate the need for using polymethylmethacrylate and internal fixation in combination when prophylactically fixing pathologic lesions of this proportion.
 ...
PMID:Strength reduction and the effects of treatment of long bones with diaphyseal defects involving 50% of the cortex. 337 7

Frequently the primary lesion of high-risk cutaneous melanoma (level III, greater than or equal to 1.5mm; greater than or equal to 1.0 mm with ulceration) is in an ambiguous lymphatic drainage site on the trunk, pelvic and shoulder girdles, and head and neck area. Lymphoscintigrams were performed by a circumferential intradermal injection of the biopsy site using technetium 99m (99mTc) antimony sulfide colloid in a total dose of 0.2 to 0.6 mCi in a volume of 0.1 to 0.5 ml. Imaging was done with a large-field gamma camera with high-resolution parallel hole collimator. Technetium 99m antimony sulfide colloid is an ideal agent for lymphoscintigrams because of small particle size (3-30 micron), which permits early migration into the interstitial space and lymphatics and rapid pickup by lymph nodes. Although it is a gamma emmitter with high activity, it has a short half-life and does not induce tissue necrosis. It does not localize the site of lymph node metastases, but indicates only the drainage pattern. Images were obtained at 1, 5, 10, 15, 30, and 60 minutes, respectively, and then three times every hour. Surgery was usually performed 24 hours later. The majority of patients had lesions with ambiguous drainage sites: head and neck (4 of 5 patients) and trunk (9 of 13 patients). The drainage by scan was to unpredictive sites in 72%, and resulted in a change of treatment planning by location and extent of ablation with node dissection in 9 of 18 patients. Ambiguous dissection sites included: (1) question of preauricular dissection with parotidectomy versus posterior auricular and cervical dissection for selected scalp lesions; (2) low-neck with or without axillary dissection for upper chest and shoulder lesions; and (3) axillary versus groin dissections for midflank lesions at zone of ambiguity between axilla and groin. It was concluded that preoperative 99mTc antimony sulfide lymphoscintigraphy is a highly useful planning technique in determining the appropriate lymphatic drainage basin for dissection in selected melanoma patients.
 ...
PMID:Radionuclide lymphoscintigraphy with technetium 99m antimony sulfide colloid to identify lymphatic drainage of cutaneous melanoma at ambiguous sites in the head and neck and trunk. 397 11

A technique is described for the intraoperative use of ultrasound sector scanning in intracerebral neoplasms (mainly gliomas) for biopsy and for the localization of minor lesions. Altogether, 13 patients underwent sonographic examination: nine had gliomas, one had a meningioma, and three had metastases. Through a trephine hole or a bone flap over the tumor, the ultrasound transducer easily localized the lesion in all cases but one. The striking concordance between the sonogram and the corresponding computerized tomography scan made it easy to take several biopsies from areas where the tumor tissue was suspected to be representative. The results show a close correlation between the biopsy specimen and the specimen obtained at extirpation. In two cases, ultrasonic scanning served as an aid for the surgeon in localizing the tumor prior to removal.
 ...
PMID:Ultrasound sector scanning for the localization and biopsy of intracerebral lesions. 684 13

Between 30 and 70% of almost one million new cancer patients diagnosed each year will develop osseous metastases. Clinicians are faced with the difficult task of determining which patients require prophylactic stabilization to prevent pathologic fracture. The objective of this study was to test the ability of macroscopic finite element models to predict the fracture strength of the proximal femur with a lesion in the femoral neck. Drill hole defects in human cadaver femora were used to simulate lesions that penetrate one cortex of the femoral neck. Based on the first of two series of in vitro experiments, the fracture strength of a femur with a lesion that penetrates either the inferior-medial or superior-lateral cortex of the neck is approximately 45% less than the fracture strength of the paired intact femur; based on the second series, the fracture strength with the inferior-medial lesion is approximately 20% less than the fracture strength with the superior-lateral lesion. A series of three-dimensional finite element models were used to predict the fracture strength for anterior and posterior lesions, as well as the inferior-medial and posterior-lateral lesions tested in vitro. Based on a direct comparison of the strengths predicted by the finite element models to the measured in vitro fracture strengths, the finite element models performed poorly. In particular, the application of an anisotropic strength criterion to the stresses predicted by the models resulted in a considerable underestimation of the percentage reduction in the in vitro fracture strength. This may reflect a fundamental inability of a linear, macroscopic continuum-based analysis to predict accurately the fracture strength of a bone structure as complex as the proximal femur. However, despite this lack of agreement in absolute fracture strength, the general trends for gait and stair ascent loading for the inferior-medial and superior-lateral lesions were consistent with the in vitro data. The greatest reduction in strength was predicted for the inferior-medial lesion, followed by the anterior lesion and then the superior-lateral lesion, and the least reduction in strength was predicted for the posterior lesion. Most importantly, the predicted strength ratio varied considerably as a function of the applied loads. Any metastatic lesions of the femoral neck may be especially sensitive to some particular activity, making it difficult to determine precisely the risk of fracture.
 ...
PMID:Evaluation of finite element analysis for prediction of the strength reduction due to metastatic lesions in the femoral neck. 846 38

The authors report on their experience of lesionectomies close to or in the thalamus, basal ganglia, third ventricle and in the temporal lobe. The resection itself is performed stereotactically, MRI or CT guided, either microscopically or endoscopically through a sleeve designed by one of the authors and named PAN working sleeve. Over the last four years this new minimally invasive technique has been successfully applied in 39 cases. Eighteen patients with 11 astrocytoma (6AA, 5All), 5 cavernoma and 2 metastases (melanoma, adenocarcinoma) of the basal ganglion-thalamus area and the trigonum were resected by means of a frontal or an occipital burr-hole, whereby in some cases there were subtotal resections. With four of these patients an existing hemiparesis increased by one degree (according to the proposal of the British Medical Research Council I-V). Seventeen patients with lesions in the foramen Monroi and in the third ventricle also underwent operation by means of frontal access, and in each case there was a total resection. Two of the patients required a shunt due to a persistent hydrocephalus internus. In one of these cases there was intraventricular bleeding which necessitated an intra-operative craniotomy. Four patients with intractable epilepsy were operated through a burr-hole in the anterior area of the os zygomaticum. Three patients were submitted to a selective resection of mesial structures and one to an anterior temporal lobe resection. To date the four patients have had no further seizures and no deficits have been observed.
 ...
PMID:Minimally invasive lesionectomies through a stereotactically guided working sleeve. 1004 56

Bone cancer pain most commonly occurs when tumors originating in breast, prostate, or lung metastasize to long bones, spinal vertebrae, and/or pelvis. Primary and metastatic cancers involving bone account for approximately 400,000 new cancer cases per year in the United States alone, and >70% of patients with advanced breast or prostate cancer have skeletal metastases. Whereas pain resulting from bone cancer can dramatically impact an individual's quality of life, very little is known about the mechanisms that generate and maintain this pain. To begin to define the mechanisms that give rise to advanced bone cancer pain, osteolytic 2472 sarcoma cells or media were injected into the intramedullary space of the femur of C3H/HeJ mice, and the injection hole was sealed using dental amalgam, confining the tumor cells to the bone. Twelve days after injection of 2472 tumor cells, animals showed advanced tumor-induced bone destruction of the injected femur, bone cancer pain, and a stereotypic set of neurochemical changes in the spinal cord dorsal horn that receives sensory inputs from the affected femur. Administration of osteoprotegerin, a naturally secreted decoy receptor that inhibits osteoclast maturation and activity and induces osteoclast apoptosis, or vehicle was begun at 12 days, when significant bone destruction had already occurred, and administration was continued daily until day 21. Ongoing pain behaviors, movement-evoked pain behaviors, and bone destruction were assessed on days 10, 12, 14, 17, and 21. The neurochemistry of the spinal cord was evaluated at days 12 and 21. Results indicated that osteoprotegerin treatment halted further bone destruction, reduced ongoing and movement-evoked pain, and reversed several aspects of the neurochemical reorganization of the spinal cord. Thus, even in advanced stages of bone cancer, ongoing osteoclast activity appears to be involved in the generation and maintenance of ongoing and movement-evoked pain. Blockade of ongoing osteoclast activity appears to have the potential to reduce bone cancer pain in patients with advanced tumor-induced bone destruction.
 ...
PMID:Osteoprotegerin diminishes advanced bone cancer pain. 1135 23


1 2 3 Next >>